Fenwick represented Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, in its $142 million combined Series A and B financing. The Series A round was led by Versant Ventures and Amplitude Ventures. The Series B round was led by venBio Partners.
This investment will be used to engineer and advance best-in-class antibody-based radiopharmaceuticals for cancer. More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partners Effie Toshav and Matt Rossiter and included associates James Li, Nikhil Sharma, Grace Fernandez and Ryan Kidman.